CatalystMarker
← board

VREOF

distress 2/10 · well-funded / low risk
$9.81+1%today-58% from 52w high
vireogrowth.com520 employeesFounded 2004Minneapolis, MNDrug Manufacturers - Specialty & Generic
Revenue
$106M
Liquidity
$145M
Runway
Shares 1y

Price & events

-39.3% over 6M
$9.56$13.36$17.16Jan 26Apr 26Jul 2654kdilution: S-3 shelf_registration (2026-04-23)financing: 8-K material_agreement (2026-06-18)financing: 8-K private_placement (2026-06-11)financing: 8-K material_agreement (2026-05-29)financing: 8-K material_agreement (2026-05-05)financing: 8-K private_placement (2026-04-14)financing: 8-K private_placement (2026-04-06)financing: 8-K material_agreement (2026-03-25)
CatalystRating changeDilutionFinancingdashed = today
+0.7%
1D
-1.8%
1W
-5.9%
1M
-34.2%
3M
-39.3%
6M
-27.3%
1Y
-27.7%
2Y
-80.8%
5Y
-78.1%
All

Overview

Volume
14.70K
52 Week Range
$9.56 – $23.10
Float Shares
28.41M
% Held by Insiders
33.16%
% Held by Institutions
7.81%
RVOL
1.06x
Beta
0.07

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 5

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: · 3 offerings/1y · 7 PIPEs
  • 2026-06-188-Kmaterial_agreement
  • 2026-06-118-Kprivate_placement
  • 2026-05-298-Kmaterial_agreement
  • 2026-05-058-Kmaterial_agreement
  • 2026-04-23S-3shelf_registration
  • 2026-04-148-Kprivate_placement
  • 2026-04-068-Kprivate_placement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.